EYE-GO

EYE-GO A/S is a Danish medical technology company established in July 2015, operating from Hørsholm, Denmark. The company was founded to address significant shortcomings in ophthalmic care, specifically the challenges patients face with traditional eye drop bottles which often lead to incorrect dosing, poor adherence to treatment, and potential disease progression.

The company's core offering is the MistGo® delivery system, a handheld device engineered to replace conventional droppers. MistGo® atomizes liquid medication into a gentle, 6 µL micro-dose mist that coats the entire cornea, ensuring precise and comfortable application with every use. This technology is designed to be compatible with preservative-free formulations, mitigating the risk of ocular surface damage associated with preservatives like benzalkonium chloride (BAK). By preventing contamination and ensuring correct dosage, MistGo® aims to improve patient compliance and therapeutic outcomes for chronic eye conditions such as glaucoma and dry eye disease.

EYE-GO's business model is centered on a B2B strategy, licensing the MistGo® platform to pharmaceutical companies. This approach involves forming partnerships for specific drug-device combinations, generating revenue through milestone payments and long-term supply agreements. The company assists its pharmaceutical partners with the increasingly stringent regulatory requirements for combination products in both the US and Europe. A significant development is the evolution towards MistGo® Digital, a connected version of the device. This next-generation platform integrates adherence monitoring capabilities, allowing patients and clinicians to track medication usage. Following a strategic investment from Topcon Healthcare in May 2025, MistGo® Digital is being integrated into Topcon's Harmony® digital health platform, combining drug delivery data with diagnostic insights to create a more comprehensive and connected care pathway.

The company is led by CEO Henrik Nagel, who joined in 2018 and has over 25 years of management experience in life science and MedTech firms like Coloplast and Ambu. The management team also includes seasoned executives with extensive backgrounds in international business development, quality assurance, and regulatory affairs from the MedTech industry. In May 2025, EYE-GO strengthened its board with the appointment of Topcon Healthcare's CEO, Ali Tafreshi, reflecting the deepening strategic partnership.

Keywords: ophthalmic drug delivery, microdosing, eye care, MedTech, MistGo, glaucoma treatment, dry eye disease, patient adherence, preservative-free, drug-device combination, digital health, connected care, pharmaceutical licensing, ocular surface, Topcon Healthcare, medication delivery system, atomization technology, patient compliance, chronic eye disease, topical therapies, controlled dosage